source
- Former Madrigal exec sues, alleging retaliation after flagging safety concerns on approved MASH drugA former senior vice president of clinical development at Madrigal Pharmaceuticals, Michael Charlton, has filed a federal lawsuit claiming he was forced to resign after raising internal safety conc…
- Novo claims 80% share of oral GLP-1 market as rivalry with Lilly intensifiesNovo's CEO Mike Maziar Doustdar said the company leads the oral GLP-1 market, stating the Wegovy pill holds about 80% of prescriptions since its launch in January. Eli Lilly, however, reported tha…